On-site at this year’s ESC Congress 2017, Philips will showcase the following ultrasound innovations:
EPIQ with HeartModel that features the X8-2t Live 3D transesophageal transducer, the next level of cardiac imaging for fast, easy, and accurate transesophageal echocardiography, enabling clinicians to diagnose surgical pathology in real time.
Affiniti, which now supports X7-2t Live 3D TEE, to deliver greater confidence and expand access to 3D transesophageal imaging to a wider range of patients.
Lumify, now with the addition of the S4-1 phased-array transducer and cardiac exam preset, to deliver exceptional cardiac imaging and triage on a compatible Android device.


Philips has a leadership position in image-guided therapy with a unique portfolio of interventional imaging systems and devices, planning and navigation software, and services, supported by a global network of leading clinical partners. Philips’ connected image-guided therapy solutions enable clinicians to decide, guide, treat and confirm the appropriate cardiac and peripheral vascular treatment. With the recent acquisition of Spectranetics’ highly competitive product range of therapeutic devices in cardiovascular interventions, Philips is advancing its solutions to deliver enhanced care for patients.
At this year’s congress, Philips will showcase its wide portfolio of integrated solutions for the interventional cardiovascular community, including:
Azurion, the next generation image-guided therapy platform, which enables clinicians to easily and confidently perform a range of routine and complex procedures, helping them to optimize interventional lab performance and provide superior care.
New instant wave-Free Ratio (iFR) technology, iFR Roadmap [1] [2], exclusive to Philips' interventional labs, which enables physicians to navigate coronary arteries and corresponding iFR data in real time.
Philips’ SyncVision iFR co-registration solution couples iFR physiology measurement pull-back results to the coronary angio, which can be utilized in the stenting process when lesions are more complex.

On August 26, 2017, as part of the ESC Congress 2017 Late Breaking Clinical Trials program, professor Javier Escaned of Hospital Clinico San Carlos in Madrid, Spain will present data from the SYNTAX II trial. The trial, which included 454 patients from 22 centers across the United Kingdom, the Netherlands, Spain and Poland, addressed the unique advantages of the state-of-the-art percutaneous coronary intervention (PCI) procedure that incorporates physiology, intravascular ultrasound (IVUS) imaging, synergy drug-alluding stents and contemporary optimal medical therapy. The physiology and IVUS imaging components are exclusively Philips technologies. The findings from the SYNTAX II trial may show that angiography alone is not enough for determining a treatment pathway for complex coronary procedures. In addition, the state-of-the-art PCI technique may also simplify procedures, and contribute to improved patient outcomes.

Cardiology Homepage